A Phase 3 interventional study of Sulfadoxine pyrimethamine and Amodiaquine in Malaria, sponsored by Malaria Consortium. Active, not recruiting at 1 site in South Sudan. Open to participants aged 3 Months to 59 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-25.
Sponsored by Malaria Consortium · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies testing amodiaquine in Malaria — 2 open to participants now, 5 under way, 2 of them phase 3. Amodiaquine · Malaria.
Among the 46 studies testing amodiaquine in Malaria, this one is the 7th largest by planned enrollment of the 44 interventional ones that give a count, is one of 4 that started in 2022, is one of 16 in phase 3, and was the 42nd registered.
1,187 studies on the registry are indexed under Malaria; 80 are open to participants now.
Browse Malaria studies →2 of the 46 studies testing amodiaquine in Malaria are open now, in 1 country. Recruiting first, the newest first:
Malaria Consortium · Sites in Burkina Faso
Ages 5–15
London School of Hygiene and Tropical Medicine
Ages 1–14 · Healthy volunteers
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 51 Malaria studies recruiting now, 15 (29%) set no upper age limit and 33 (65%) stop at 75 or younger; 37 take children under 18; 31 take healthy volunteers.
This study: 3 Months to 59 Months · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 7 · Phase 3 17 · Phase 4 18
First in 2001; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 3,575 is above the median of 252 across 939 interventional studies indexed under Malaria.
Median enrollment 738 across the 44 interventional studies. Of the 38 that completed or were terminated, 2 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 46 have an industry lead sponsor. The 10 most frequent:
Malaria Consortium is the lead sponsor of 15 studies on the registry; 4 are open to participants now.
10 studies in Malaria by Malaria Consortium: 3 open now, 9 under way, 2 of them phase 3. Of 1 finished, 0 (0%) have results posted.
Among the 10 studies in Malaria by Malaria Consortium, this one is one of 4 that started in 2022, is one of 2 in phase 3, and was the 4th registered.
Malaria Consortium’s Malaria studies by the year they started, since 2013.
None of the studies under way reaches primary completion within a year.
Among the 46 studies testing amodiaquine in Malaria, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Malaria Consortium’s 10 in Malaria:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study aims to explore whether SMC is an effective intervention in the context of Northen Bahr el Gazal state, South Sudan. It also aims to assess the protective efficacy of the antimalarials used in SMC in the target population and investigate levels of parasite resistance in the study counties. If successful, this trial should provide the evidence for SMC to be included in malaria programming and policy in South Sudan.
A Type II hybrid effectiveness-implementation study design will be used to evaluate the effects of a clinical intervention on relevant outcomes whilst collecting information on implementation. It is designed to determine feasibility and effectiveness of an innovative intervention, as well as the protective efficacy of the antimalarial drugs used. The study consists of five components: 1) A series of cross-sectional surveys establishing confirmed malaria cases in children; 2) A prospective cohort study to determine the protective efficacy of SPAQ (if SPAQ provides 28 days of protection from infection) and whether drug concentrations and/or resistance influence the duration of protection; 3) A resistance markers study in children 3-59 months in the research county; 4) Modelling the protective effect of SPAQ in South Sudan to determine where SMC could be a suitable malaria prevention strategy in other areas of the country, and 5) A process evaluation to understand feasibility and acceptability of the SMC intervention in South Sudan.
This is an implementation research study, using a Type II hybrid effectiveness-implementation study design, to evaluate the effects of a clinical intervention on relevant outcomes whilst collecting information on implementation.
The study uses pragmatic implementation research with the objective of contributing to the development of practical recommendations for health policy, practice and potential scale up. It is designed as an implementation study to determine effectiveness and protective efficacy to gather evidence of its potential impact on health outcomes. Five monthly cycles of SMC will be implemented between June and October 2022 in one county, Aweil South, in Northern Bahr el Gazal state.
The study will comprise the following six components :
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Children aged 3-59 months will receive SPAQ in the intervention arm
Drug: Sulfadoxine pyrimethamine · Drug: Amodiaquine
Children aged 3-59 months will not receive SPAQ in the control arm
Sulphadoxine is a slowly eliminated sulphonamide. It is used in a fixed dose combination of 20 parts sulphadoxine with 1 part pyrimethamine given orally or intramuscularly. The medicine is no longer recommended for the treatment of malaria. However, it is being used for Intermittent Preventive Treatment during pregnancy (IPTp) and as a co-packaged combination with amodiaquine for seasonal malaria chemoprevention. Sulphadoxine is readily absorbed from the GIT. It is widely distributed in body tissues and fluids and crosses the placenta into foetal circulation. It is also readily detectable in breast milk. It is excreted predominantly as the unchanged drug.
Also known as: SP
Amodiaquine is a Mannich base 4 amino-quinoline that interferes with parasite haem detoxification. It is more effective than chloroquine in both chloroquine sensitive and resistant P. falciparum infections. However, there is cross-resistance between chloroquine and amodiaquine. It is readily absorbed in the GIT and rapidly converted in the liver to the active metabolite, desethylamodiaquine. Desethylamodiaquine is responsible for all the antimalarial effect.
Also known as: AQ
Malaria incidence in study population in intervention county and eligible children in one control county
Number of malaria cases in the intervention population and eligible children in one control county over the study period as reported through care givers in cross-sectional surveys at baseline, mid-intervention and endline
Time frame: Five months
Chemoprevention failure as defined by positive parasites in malaria slides after day 7 or positive qPCR in dried blood spot (DBS) on day 28
Malaria slides and dry blood spots (DBS) taken at days 0,7, 28 will be analysed with qPCR methodology to detect low level submicroscopic parasitemia in children treated with SPAQ
Time frame: One month
Prevalence of antimalarial resistance markers (dhfr, dhps, Pfcrt, pfmdr1) among chemoprevention failures as defined in outcome 2
All Dried blood spots (DBS) will be analysed for malaria mutation genotypes (dhfr, dhps, Pfcrt, pfmdr1) on baseline and endline and additionally on day 7, day 28, or if participant slide is positive for parasites on day 7 or an infection is reported through care givers in cross-sectional survey.
Time frame: One month
Drug concentrations of Sulfadoxine-pyrimethamine and amodiaquine among chemoprevention failures (as defined in outcome 1)
Drug concentrations will be analyzed for all samples on baseline, day 7 and day 28 and will be linked to chemoprevention failure cases as defined in outcome 2 or a malaria infection is reported through care givers in cross sectional survey.
Time frame: One month
Plan to share: No — As this data is sensitive we propose not to share it.
No publications or documents are linked to this record.
Started Jul 2022 (actual). Primary completion is estimated for Dec 2024, 28 months after the start.
Of 44 non-industry phase 3 interventional studies under Malaria, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 34. This study's planned 28 months is above that.
Counting every sponsor, half of 50 studies reached it within 23 months; a quarter within 17 and three quarters within 31.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Amodiaquine
Malaria Consortium